http://biz.yahoo.com/ic/news/516.htmlThe latest news on the Diagnostic Substances industry from Yahoo! Financeen-USFri, 25 May 2012 15:14:02 GMThttp://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif14445http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=13243edj1/*http://www.fool.com/investing/general/2012/05/23/how-fast-is-the-cash-at-idexx-laboratories.aspx?ticker=IDXX&source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/1610536749Fri, 25 May 2012 15:14:02 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/study-validating-mirview-mets2-published-142800723.html[Marketwire] - PHILADELPHIA, PA and REHOVOT, ISRAEL-- - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that data from studies of miRview® mets² ...yahoo_finance/1990878502Fri, 25 May 2012 14:28:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/surmodics-inc-srdx-050002894.htmlyahoo_finance/302560231Fri, 25 May 2012 05:00:02 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/rosetta-genomics-raise-6-6-233600452.html[Marketwire] - PHILADELPHIA, PA and REHOVOT, ISRAEL-- - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostics, today announced it has entered into definitive agreements with ...yahoo_finance/484532483Thu, 24 May 2012 23:36:00 GMThttp://us.rd.yahoo.com/finance/external/theflyonthewall/rss/SIG=13701urv5/*http://www.theflyonthewall.com/permalinks/entry.php/ROSGid1642141/ROSG-Rosetta-Genomics-names-new-CFOyahoo_finance/661251600Thu, 24 May 2012 20:20:34 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/securealert-inc-announces-record-six-193900586.htmlyahoo_finance/3991899630Thu, 24 May 2012 19:39:00 GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=134gbl8gt/*http://www.fool.com/investing/general/2012/05/24/1-reason-to-expect-big-things-from-surmodics.aspx?ticker=SRDX&source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/2039404368Thu, 24 May 2012 14:06:29 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/appointment-scott-r-ward-creganna-140000868.html[Business Wire] - Scott R. Ward has been appointed as Chairman of Creganna-Tactx Medical, a leading provider of medical device outsourcing solutions. Mr. Ward will succeed, Mr. Ian Quinn, the companyahoo_finance/2862581861Thu, 24 May 2012 14:00:00 GMThttp://us.rd.yahoo.com/finance/external/minyanville/rss/SIG=14d76b09n/*http://www.minyanville.com/trading-and-investing/stocks/articles/stocks-trading-equities-investing-investments-investors/5/24/2012/id/41225?camp=syndication&medium=portals&from=yahoo[at Minyanville] - Celldex Therapeutics was up this morning.yahoo_finance/4073362196Thu, 24 May 2012 13:30:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/aspenbio-appoints-diagnostics-industry-veteran-132200342.html[Business Wire] - AspenBio Pharma, Inc. , today announced that Don Hurd has been appointed to the new position of Senior Vice President and Chief Commercial Officer, effective May 23, 2012.yahoo_finance/62406162Thu, 24 May 2012 13:22:00 GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12m15ed81/*http://www.reuters.com/article/2012/05/23/celldex-breastcancer-idUSL1E8GNIJS20120523?feedType=RSS&feedName=marketsNews&rpc=43yahoo_finance/3185492138Wed, 23 May 2012 22:36:42 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/abaxis-remains-neutral-202020041.htmlyahoo_finance/2388521276Wed, 23 May 2012 20:20:20 GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12mm35t0o/*http://www.reuters.com/article/2012/05/23/celldex-breastcancer-idUSL1E8GNDW120120523?feedType=RSS&feedName=rbssHealthcareNews&rpc=43yahoo_finance/416194496Wed, 23 May 2012 20:01:54 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/celldex-cdx-011-demonstrates-high-200100503.html[Business Wire] - Celldex Therapeutics, Inc. today announced preliminary results from the Company’s randomized Phase 2b EMERGE study of CDX-011 antibody drug conjugate in patients with glycoprotein NMB expressing, advanced, heavily pretreated breast cancer.yahoo_finance/1495818343Wed, 23 May 2012 20:01:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/inolife-technologies-appoints-marketing-specialists-132530825.htmlyahoo_finance/3958977806Wed, 23 May 2012 13:25:30 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/large-pharmaceuticals-look-biotech-industry-122000450.html[Marketwire] - NEW YORK, NY-- - In recent months the Biotech Industry has become a hotbed of Merger and Acquisition activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked ...yahoo_finance/728707377Wed, 23 May 2012 12:20:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/website-reflects-strategic-focus-120000658.html[Business Wire] - SurModics, Inc. , a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, is pleased to announce the launch oyahoo_finance/489348247Tue, 22 May 2012 12:00:00 GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=136i6gdsj/*http://www.fool.com/investing/general/2012/05/21/something-worth-watching-at-idexx-laboratories.aspx?ticker=IDXX&source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/2538407902Mon, 21 May 2012 15:22:10 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/positive-data-nx-1207-presented-133000249.html[GlobeNewswire] - HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held Sunday at the Annual Meeting ...yahoo_finance/1957955916Mon, 21 May 2012 13:30:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/celldex-therapeutics-host-call-announce-143000525.html[Business Wire] - Celldex Therapeutics, Inc. will host a conference call at 4:30 P.M. Eastern Time on Wednesday, May 23, 2012 to announce interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer.yahoo_finance/1975136272Fri, 18 May 2012 14:30:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/tapimmune-announces-appointment-james-w-131500353.htmlyahoo_finance/4041612508Fri, 18 May 2012 13:15:00 GMT